Business Context and Reporting Period
This Form 8-K Current Report was filed by Amphastar Pharmaceuticals, Inc. on January 12, 2026, covering events that occurred on January 6, 2026. The filing details the entry into a new exclusive License Agreement and amendments to existing Distribution and Manufacturing Agreements with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin"). These transactions are classified as related party transactions, as Amphastar's executive leadership and their families hold a majority equity interest in Hanxin.
Key Financial Metrics and Transaction Terms
The filing outlines specific financial commitments associated with the new License Agreement for a corticotropin compound:
- Upfront Payment: $2 million paid to Hanxin upon signing.
- Development Milestones: Up to $14 million contingent on achieving specific development events.
- Sales Milestones: Up to $75 million contingent on achieving specific sales targets.
- Royalties: Amphastar will pay Hanxin royalties with a maximum annual cap of $7.5 million and a maximum accumulated cap of $60 million.
- Reciprocal Royalties: Hanxin will pay Amphastar royalties on net sales based on patents or regulatory exclusivity licensed by Amphastar to Hanxin.
The filing does not provide current period revenue, profit, cash flow, or debt figures, as this is a current report regarding specific agreements rather than a periodic financial statement.
Material Changes and Agreements
Three primary agreements were executed or amended on January 6, 2026:
- License Agreement: Grants Amphastar an exclusive license to develop and commercialize a corticotropin product in the United States and Canada. Hanxin receives a non-exclusive license for territories outside the U.S. and Canada.
- Distribution Amendment: Expands the geographic scope of the existing distribution agreement to include Middle East and Southeast Asian countries. The Company states the change in value is not determinable and does not expect the amendment to be material to financial conditions.
- Manufacturing Amendment: Expands the manufacturing territory globally (excluding the U.S. and Canada for Lidocaine and Corticotropin) and adds global rights for Semaglutide active pharmaceutical ingredients and finished tablets (3, 7, and 14 mg doses). The Company does not consider this amendment material to its financial condition.
Outlook, Risks, and Related Party Considerations
Related Party Transactions: The Audit Committee of the Board of Directors evaluated and approved the Distribution and Manufacturing Amendments. The transactions involve Hanxin, in which Dr. Jack Zhang (CEO) and Dr. Mary Luo (Chairman) beneficially own a majority of the equity interest.
Forward-Looking Statements: The filing includes standard disclaimers regarding forward-looking statements, noting that actual results may differ due to risks such as changes in laws, regulations, and supply chain disruptions. The Company undertakes no obligation to update these statements.
Materiality: While the License Agreement involves significant potential payments, the Company explicitly states that the Distribution and Manufacturing Amendments are not expected to be material to its financial conditions or results of operations.
Investor Verification Checklist
- Verify the full text of the License Agreement, Distribution Amendment, and Manufacturing Amendment, which are filed as exhibits to the upcoming Form 10-K for the fiscal year ending December 31, 2025.
- Review the related party transaction disclosures in the Company's Definitive Proxy Statement (Schedule 14A) filed on April 14, 2025, to understand the extent of executive ownership in Hanxin.
- Monitor future filings for the achievement of the $14 million in development milestones and the $75 million in sales milestones.
- Confirm the specific terms of the reciprocal royalty payments from Hanxin to Amphastar in the final executed agreements.